Background Hepatitis C is a major public health problem of increasing importance among injecting drug users, among whom screening has been proposed. We therefore estimated the cost utility of screening for hepatitis C infection among people with a history of injecting drug use in contact with drug misuse services.
Introduction
Hepatitis C virus (HCV) is an important public health problem, affecting up to 1 per cent of the general population. Chronicity of infection occurs in up to 85 per cent, and the consequences of chronic infection contribute significantly to the global burden of disease -including need for liver transplantation.
Screening for HCV in injecting drug users (IDUs) has been supported by a range of professional consensus statements. [1] [2] [3] [4] In the United Kingdom, the Advisory Council on the Misuse of Drugs has advised that 'agencies should ensure that screening for virus infection is routinely and appropriately used, with preand post-test counselling on the implications of results'. 5 The Government has responded by stating that drug users who are or have been at risk should be offered well-informed advice and should be made aware of the implications of a postive test. Although these recommendations constitute a policy in favour of screening for HCV for IDUs, some issues are unclear. How far should opportunities for voluntary testing be expanded and will there be a trade-off between equity and efficiency (e.g. would voluntary testing be taken up by those who stand to benefit directly from screening)? The levels at which prevalence should be defined as high are not clear and agencies that should consider routine screening (the meaning of which is not defined) are not specified.
As part of a wider assessment of screening for hepatitis C, we estimated the cost utility associated with screening and treating injecting drug users in a prevalent round of screening.
Methods
We developed a model of a screening programme in Microsoft Excel, integrating a simple epidemiological model of screening Screening for Hepatitis C in injecting drug users: a cost utility analysis and diagnosis with a Markov chain model of treatment with combination therapy using interferon alpha and ribavirin. The treatment element of the model was developed to inform the National Institute for Clinical Excellence (NICE) guidance on combination therapy, published in 2001. 6 The perspective of the model is the National Health Service (NHS) and the approach is deterministic, yielding an estimate of cost-utility (£/quality adjusted life year (QALY)) of screening versus not screening. The model examines a single round of screening in a hypothetical cohort, i.e. a prevalent round of screening. It does not address the issue of screening interval, taking account of the risk of reinfection in screened individuals, nor of repeated offers of screening to individuals who initially decline invitation. We assumed that only people who are not currently injectors would be eligible for treatment (following current recommendations for treatment 7 ). Overall, the model investigates the three main elements of the screening programme, as follows.
( 8 Proportion of males and females are assumed to be equal. The model runs for 50 years and simulates the natural history of infection for those people who respond to treatment, and in whom sustained viral clearance is assumed to indicate eradication of infection. Transition probabilities between health states for each year of the cohort were estimated from a range of studies, which are detailed in the assessment report of interferon treatment considered by NICE 6 and summarized in Table 2 . Death rates from unrelated causes were estimated from British life tables. 9 The screening and diagnostic elements of the model are outlined in Fig. 1 , which also shows assumptions regarding additional health service usage during these stages. People who reach the final stage in the screening and diagnostic elements move on to the treatment element, which is shown in Fig. 2 . This small group from the original cohort are those for whom the impact of treatment on the natural history of HCV is modelled. 1 It is assumed that those who respond to treatment will avoid the adverse health states associated with long-term chronic HCV and that the costs of treatment associated with these states are averted, giving an estimate of cost per QALY for successful treatment.
Screening is compared with a no screening scenario, in which people with HCV would have presented for treatment 11 years later with symptoms. This period was taken from the difference in mean age between patients enrolled in screening studies 8 and those enrolled in treatment for HCV controlled trials. 10 We carried out a range of literature searches to inform the parameters of the model, using the following databases For the base case estimates, values were chosen from studies on the basis of methodological quality of the study, how recently the study was published, the relevance to the United Kingdom setting, the generalizability of the study population to the current question and the sample size of the study. Where possible, we used existing systematic reviews of good quality. The model by Shepherd et al. 6 used in the NICE appraisal of the cost effectiveness of combination therapy was used to estimate the benefits and costs associated with treating people found to be HCV positive on screening. 6 We performed a further search forwards from that review (years 2000-2001) for relevant studies. We used the same search strategy and inclusion and exclusion criteria as in the previous assessment, 6 seeking further randomized controlled trials (RCTs) and systematic reviews. Two recently published systematic reviews on the effectiveness of therapy 11, 12 were reviewed. The model of Shepherd et al. 6 was updated by revision of cost data, obtained from a range of routine sources.
Costs were estimated from a range of sources and are detailed in Tables 1 and 2 . The base year for cost estimates was 2001 and costs were discounted at 6 per cent. Benefits were discounted at 1.5 per cent. We incorporated limited follow-up of people who were not included in the treated cohort, based on out-patient costs of £50-100 and 50-80 per cent attendence.
We carried out a wide range of one-way sensitivity analyses to investigate the uncertainty in our results associated with plausible variation in the values of inputs. We included an estimate of the possible cost effectiveness of screening with treatment with pegylated interferon, for which evidence is currently emerging. 
Results
We found no more recent information on the effectiveness of combination therapy than was included in the review by Shepherd et al. and so their estimates for sustained virological response rates on combination therapy were employed (33 per cent at 24 weeks and 41 per cent at 48 weeks). The summary results of the base case analysis are shown in Table 3 . It is likely that screening would yield benefits at a cost of around £28 000 per QALY. Using pegylated interferon may be more cost effective in the context of a screening programme, the cost per QALY being around £14 000. More favourable cost effectiveness is achieved through higher response rates and lower dose requirements for ribavirin. Pegylated interferon is more expensive than conventional interferons.
The sensitivity analysis (see Table 4 ) showed that the base case estimate was not subject to substantial change as a result of uncertainty in the following parameters, across a plausible range of variation in each:
• the proportion of the cohort who were current IDUs and therefore ineligible for screening; • the underlying prevalence of HCV in populations presenting to drug services; • the proportion of eligible people presenting who accept ELISA testing; • the proportion of people who accept PCR testing;
• the sensitivity and specificity of ELISA;
• the sensitivity and specificity of PCR.
The base case estimate changes considerably with variation in the following parameters, and decisions regarding the implementation of HCV screening based on cost effectiveness criteria may be importantly sensitive to uncertainty in these factors:
• the proportion of HCV positive people who accepted a liver biopsy (see Fig. 3 ). The cost per QALY increases rapidly once acceptance rates fall below 30 per cent; • the proportion of people who accept treatment (see Fig. 4) ; • treatment response. When treatment response decreases below 30 per cent the resulting cost per QALY rises dramatically (see Fig. 5 ). The cost per QALY becomes substantially lower as treatment response rate rises above 50 per cent; • the proportion of people eligible for treatment, i.e. case mix.
Where only 20 per cent of those identified through screening have moderate chronic hepatitis and are eligible for treatment, cost per QALY is £135 000; • the mortality rate associated with biopsy complications:
where biopsy mortality is 0 per cent, cost per QALY is £22 000, rising to £38 000 when mortality is 0.06 per cent;
• assigning those who are current IDUs (and therefore ineligible for treatment) a follow-up out-patient appointment raises the cost per QALY to £37 000; • the utility assigned to the health state of chronic hepatitis: when this is set to 0.8, cost per QALY falls to £11 000; • utility of successful drug treatment. When this is reduced to 0.90, cost per QALY increases to £278 372.
Discussion
This study has improved on previous evaluations of screening for hepatitis C. [13] [14] [15] [16] [17] [18] Most of the previous studies were set outside the United Kingdom and did not attempt an evaluation of the cost effectiveness of the entire screening programme (i.e. including diagnosis and treatment). Our previous study in this area 18 was limited methodologically by the absence of a clear comparison with no-screening and poor natural history data within the treatment element of the model. These issues have been addressed in the current study, which also includes more extensive information on adherence, which is an area of considerable uncertainty.
However, some methodological limitations remain. The model does not stratify for age at identification and if the real population being screened is skewed towards those younger than the average of 32 assumed in the model then the cost utility ratio will have been overestimated. Conversely, if the true population distribution is negatively skewed, then the model may have incorporated an element of over-treatment and underestimated cost utility, as people who would not have experienced problems would have been unnecessarily treated. Death rates are from standard life tables, which are likely to underestimate the force of mortality in IDUs and therefore underestimate the cost utility ratio. The number of IDUs varies within England, with London and the North West having high rates. This will affect the cost of screening programmes. Effects on cost effectiveness depend on a range of other variables, including prevalence, acceptance and adherence, on which we have few data on geographical variation.
The model incorporates treatment for people who are not identified by screening, but does this by assuming that they are identified, on average, 11 years later than they would have been in the presence of screening. This assumption is untested and would require more sophisticated modelling techniques to explore than have been employed in the current study.
The quality of evidence underlying the estimates used in the model varies. Evidence for the effectiveness of treatment with combination therapy is of high quality but costing information is much more limited. Sources for the costs of treating complications of HCV infection are drawn from routine NHS sources and are predominantly driven by length of hospital stay. More detailed HCV-specific costs would enhance the model. We have not included the cost of psychiatric assessment, which may be common among those being considered for treatment, and have not incorporated any estimate for the psychological distress in false positive cases.
We linked eligibility for screening with eligibility for treatment; i.e. people who are currently injectors would not be considered eligible for treatment. Other criteria affecting eligibility for treatment in clinical use (e.g. alcohol consumption, psychiatric status) have not been considered. The effect of this is to bias the model in favour of screening.
The model takes no account of rates of non-attendance in health services at the various stages of screening, diagnosis and treatment. It will therefore underestimate the true cost of screening as average out-patient clinic costs do not take account of the loss of productivity caused by wastage. The sometimes chaotic lifestyles of many HCV positive IDUs is well recognized. During 8 years experience in a regional centre, Jowett et al. 19 reported the mean number of missed appointments per person at nearly three and that 747 clinic appointments were wasted through non-attendance (30 per cent of the total).
Many of the estimates for the utilities associated with relevant health states in the model are taken from a study of US hepatologists. There is some evidence that physicians differ in their valuation of health states from other professionals, but in the case of hepatitis C the only study that we are aware of that has examined this issue reported close congruence of views. 20 Whether the utilities of health states used in economic evaluations should be measured by people experiencing those states, health care professionals acting as their proxies or by members of the general public is a point of methodological debate. Ideally, utility estimation should also take account of quality of life at different ages. Estimates used in the model for all treated people are set at 0.95 and do not vary with age. Between the ages of 45 and 49, the average QALY score estimated from a population sample in the United Kingdom was 0.84 and 0.7 at the age of 82. The utility of chronic active hepatitis (0.89) prior to diagnosis and treatment is also important given the structure of the model. We have assumed that people who are identified through screening are treated 11 years earlier than they otherwise would have been and that following successful treatment, utility would be 0.95. The difference between pre-and posttreatment utilities is therefore applied to the 11 year period and, as most people are in the chronic hepatitis state, this utility contributes considerably to the calculation of benefits. The importance of this factor is demonstrated in the sensitivity analysis, where reducing utility of successful drug treatment to 0.90 results in an estimate of cost utility approaching £280 000. It is not clear whether the utility associated with chronic hepatitis varies between people who would be identified through screening and those identified through symptomatic presentation. Quality of life studies of HCV, which emphasize the decrements in quality of life associated with chronic hepatitis, have mostly been carried out in the context of RCTs of interferon and it is not clear whether participants were identified through screening or presented to health services with symptoms. The utility modelled for chronic HCV without cirrhosis was estimated by a group of patients but the circumstances of their diagnoses are not reported. If the utility of chronic active hepatitis that would be identified through screening is higher than we have estimated and the utility following treatment is lower, then the benefits of screening may diminish considerably.
Two factors may mean that the number of people considered for screening in this study may increase in the future. First, our findings are based on IDUs in contact with drug services, which is a small minority of IDUs in the community. 21 Current efforts to increase provision of needle exchange programmes and supervised consumption of controlled drugs will increase the potential number of people considered for screening. 5 Drug misuse statistics show a steady increase in the number of service users. 22 Second, if treatment is made available to IDUs who are currently injecting, as has been suggested, 23, 24 the number of people who may be included in screening would increase by at least 25 per cent over the estimates used in this study. Whether existing information on acceptability and adherence of screening would be relevant in this extended group is uncertain.
In conclusion, we believe that screening for HCV in IDUs in contact with services is moderately cost effective (around £30 000 per QALY) and reasonably stable when explored in extensive one-way sensitivity analyses. However, uncertainties remain, some of which have a large effect on the precision of our estimate; for example, the utility gain associated with successful drug treatment following screening, acceptability of screening and adherence to treatment. Although it is likely that screening is cost effective in practice, further research (e.g. based on discrete event simulation) may be helpful in examining the effect of uncertainty in more detail and overcoming some of the structural limitations of the modelling approach taken here.
